WASHINGTON,
Dec. 6,
2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR)
("Danaher") announced today it has completed its acquisition of
Abcam plc (NASDAQ:ABCM) ("Abcam").
The acquisition of Abcam for $24.00 per share in cash was implemented by way
of a Court-sanctioned scheme of arrangement under the UK Companies
Act 2006 (the "Scheme") and the Scheme became effective in
accordance with its terms on December 6,
2023. As a result, Abcam has become an indirect wholly owned
subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has
been suspended.
The consideration due to former Abcam
shareholders will be settled pursuant to the terms of the Scheme
and the consideration due to former Abcam ADS holders will be
settled by the Depositary pursuant to the terms of the Deposit
Agreement, in each case as further described in the shareholder
circular relating to the Scheme, which was published by Abcam on
October 5, 2023.
ABOUT DANAHER
Danaher is a leading
global life sciences and diagnostics innovator, committed to
accelerating the power of science and technology to improve human
health. Our businesses partner closely with customers to solve many
of the most important health challenges impacting patients around
the world. Danaher's advanced science and technology - and proven
ability to innovate - help enable faster, more accurate diagnoses
and help reduce the time and cost needed to sustainably discover,
develop and deliver life-changing therapies. Focused on scientific
excellence, innovation and continuous improvement, our 65,000+
associates worldwide help ensure that Danaher is improving quality
of life for billions of people today, while setting the foundation
for a healthier, more sustainable tomorrow. Explore more
at www.danaher.com.
Danaher Corporation, 2200 Pennsylvania Avenue, N.W., Suite 800W,
Washington, D.C. 20037, Telephone:
(202) 828-0850, Fax: (202) 828-0860
View original
content:https://www.prnewswire.com/news-releases/danaher-completes-acquisition-of-abcam-302007456.html
SOURCE Danaher Corporation
